IDiyas

For the Inventor, By the Inventor

Waltham, MA, United States of America

Michael Howard Block

USPTO Granted Patents = 12 

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 42(Granted Patents)


Location History:

  • Macclesfield Cheshire, GB (2004)
  • Macclesfield, GB (2002 - 2005)
  • Waltham, GB (2009)
  • Waltham, MA (US) (2008 - 2011)

Company Filing History:

goldMedal12 out of 1,500 
 
Astrazeneca Ab
 patents

Years Active: 2002-2011

Loading Chart...
12 patents (USPTO):Explore Patents
1. 7951830 - Compounds effecting glucokinase (2011-05-31),
2. 7524957 - Compounds effecting glucokinase (2009-04-28),
3. 7498333 - Enantiomers of selected fused heterocyclics and uses thereof (2009-03-03),
4. 7408064 - Carbazole derivatives and their use as NPY5 receptor antagonists (2008-08-05),
5. 7390908 - Compounds effecting glucokinase (2008-06-24),
6. 7332492 - Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor (2008-02-19),
7. 6967216 - Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor (2005-11-22),
8. 6960688 - Use of compounds for the elevation of pyruvate dehydrogenase activity (2005-11-01),
9. 6878712 - Amides as inhibitors for pyruvate dehydrogenase (2005-04-12),
10. 6689909 - Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity (2004-02-10),
11. 6552225 - Chemical compounds (2003-04-22),
12. 6498275 - Use of compounds for the elevation of pyruvate dehydrogenase activity (2002-12-24),

Title: A Profile of Inventor Michael Howard Block

Introduction

Michael Howard Block, an accomplished inventor based in Waltham, MA, is known for his significant contributions to medicinal chemistry with a focus on compounds that affect glucokinase. With a total of 12 patents to his name, Block has impacted both the field of diabetes treatment and pharmaceutical research.

Latest Patents

Block's latest patents revolve around compounds that influence glucokinase (GLK). His inventions include the development of a medicament designed for the treatment or prevention of disease conditions mediated through GLK, such as type 2 diabetes. The patents detail a novel group of compounds represented by a specific formula, along with methods for the synthesis of these compounds. This innovative work addresses a critical need in managing diabetes through targeted pharmaceutical interventions.

Career Highlights

Currently employed by AstraZeneca AB, Michael Howard Block plays a vital role in advancing the company's research efforts in drug discovery and development. His expertise in designing compounds that interact with biological pathways has set a standard in the industry for therapeutic innovation. Block's commitment to enhancing patient outcomes through scientific research is evident in his extensive patent portfolio.

Collaborations

Throughout his career, Block has collaborated with esteemed colleagues, including Roger John Butlin and Thorsten Nowak. These collaborations have contributed to the successful development of innovative medicinal compounds and have fostered a productive research environment at AstraZeneca AB.

Conclusion

Michael Howard Block continues to be a pivotal figure in the realm of medicinal chemistry, leveraging his patent portfolio to drive advancements in diabetes treatment. His innovative mindset and collaborative efforts position him as an influential inventor within the pharmaceutical industry, contributing significantly to improving healthcare outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…